JP2019524772A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524772A5 JP2019524772A5 JP2019505229A JP2019505229A JP2019524772A5 JP 2019524772 A5 JP2019524772 A5 JP 2019524772A5 JP 2019505229 A JP2019505229 A JP 2019505229A JP 2019505229 A JP2019505229 A JP 2019505229A JP 2019524772 A5 JP2019524772 A5 JP 2019524772A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- treating
- disease
- liver
- hyperlipidemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 12
- 208000028867 ischemia Diseases 0.000 claims description 12
- 229920000858 Cyclodextrin Polymers 0.000 claims description 10
- 201000004624 Dermatitis Diseases 0.000 claims description 10
- 208000027418 Wounds and injury Diseases 0.000 claims description 10
- 230000006378 damage Effects 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000014674 injury Diseases 0.000 claims description 10
- 230000004064 dysfunction Effects 0.000 claims description 8
- 208000019423 liver disease Diseases 0.000 claims description 8
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 8
- 210000000056 organ Anatomy 0.000 claims description 8
- 206010040882 skin lesion Diseases 0.000 claims description 8
- -1 cyclic oligosaccharide Chemical class 0.000 claims description 7
- 229920001542 oligosaccharide Polymers 0.000 claims description 7
- 208000001395 Acute radiation syndrome Diseases 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 206010068142 Radiation sickness syndrome Diseases 0.000 claims description 6
- 206010040047 Sepsis Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 230000003902 lesion Effects 0.000 claims description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- 206010067125 Liver injury Diseases 0.000 claims description 4
- 150000002009 diols Chemical class 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000006372 lipid accumulation Effects 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 4
- 231100000234 hepatic damage Toxicity 0.000 claims description 3
- 230000008818 liver damage Effects 0.000 claims description 3
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010019663 Hepatic failure Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- PIUZYOCNZPYXOA-ZHHJOTBYSA-N [(3s,8s,9s,10r,13r,14s,17r)-17-[(2r)-6-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCCC(C)(C)O)C)[C@@]1(C)CC2 PIUZYOCNZPYXOA-ZHHJOTBYSA-N 0.000 claims description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 2
- 210000002216 heart Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 230000005976 liver dysfunction Effects 0.000 claims description 2
- 208000007903 liver failure Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 229960005489 paracetamol Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 235000013772 propylene glycol Nutrition 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims 4
- 230000037356 lipid metabolism Effects 0.000 claims 2
- 230000013190 lipid storage Effects 0.000 claims 2
- 230000004060 metabolic process Effects 0.000 claims 2
- 231100000444 skin lesion Toxicity 0.000 claims 2
- DTGDZMYNKLTSKC-HKQCOZBKSA-N cholest-5-ene Chemical compound C1C=C2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 DTGDZMYNKLTSKC-HKQCOZBKSA-N 0.000 claims 1
- DTGDZMYNKLTSKC-UHFFFAOYSA-N cholest-5-ene Natural products C1C=C2CCCCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 DTGDZMYNKLTSKC-UHFFFAOYSA-N 0.000 claims 1
- 229910021653 sulphate ion Inorganic materials 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 4
- 230000030833 cell death Effects 0.000 description 3
- 150000005215 alkyl ethers Chemical group 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022122494A JP7487264B2 (ja) | 2016-08-02 | 2022-08-01 | ５－コレステン－３，２５－ジオール，３－サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物 |
| JP2024075682A JP2024105442A (ja) | 2016-08-02 | 2024-05-08 | ５－コレステン－３，２５－ジオール，３－サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662370024P | 2016-08-02 | 2016-08-02 | |
| US62/370,024 | 2016-08-02 | ||
| US201762470578P | 2017-03-13 | 2017-03-13 | |
| US62/470,578 | 2017-03-13 | ||
| PCT/US2017/044840 WO2018026781A1 (en) | 2016-08-02 | 2017-08-01 | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022122494A Division JP7487264B2 (ja) | 2016-08-02 | 2022-08-01 | ５－コレステン－３，２５－ジオール，３－サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019524772A JP2019524772A (ja) | 2019-09-05 |
| JP2019524772A5 true JP2019524772A5 (enExample) | 2020-08-20 |
Family
ID=61073854
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505229A Pending JP2019524772A (ja) | 2016-08-02 | 2017-08-01 | ５−コレステン−３，２５−ジオール，３−サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物 |
| JP2022122494A Active JP7487264B2 (ja) | 2016-08-02 | 2022-08-01 | ５－コレステン－３，２５－ジオール，３－サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物 |
| JP2024075682A Pending JP2024105442A (ja) | 2016-08-02 | 2024-05-08 | ５－コレステン－３，２５－ジオール，３－サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022122494A Active JP7487264B2 (ja) | 2016-08-02 | 2022-08-01 | ５－コレステン－３，２５－ジオール，３－サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物 |
| JP2024075682A Pending JP2024105442A (ja) | 2016-08-02 | 2024-05-08 | ５－コレステン－３，２５－ジオール，３－サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物 |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US20190269695A1 (enExample) |
| EP (2) | EP3494125B1 (enExample) |
| JP (3) | JP2019524772A (enExample) |
| KR (3) | KR102465046B1 (enExample) |
| CN (2) | CN116747233A (enExample) |
| AU (2) | AU2017305239C1 (enExample) |
| CA (1) | CA3031224A1 (enExample) |
| CY (1) | CY1125567T1 (enExample) |
| DK (1) | DK3494125T3 (enExample) |
| EA (1) | EA201990438A1 (enExample) |
| ES (1) | ES2922933T3 (enExample) |
| HR (1) | HRP20220932T1 (enExample) |
| HU (1) | HUE059768T2 (enExample) |
| IL (2) | IL298681A (enExample) |
| LT (1) | LT3494125T (enExample) |
| MX (2) | MX2019001323A (enExample) |
| PL (1) | PL3494125T3 (enExample) |
| PT (1) | PT3494125T (enExample) |
| RS (1) | RS63529B1 (enExample) |
| SI (1) | SI3494125T1 (enExample) |
| SM (1) | SMT202200330T1 (enExample) |
| TW (2) | TWI920454B (enExample) |
| WO (1) | WO2018026781A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| EA201990684A1 (ru) | 2013-12-24 | 2020-12-30 | Вирджиния Коммонвелт Юниверсити | Способы применения оксигенированных холестеролсульфатов (ocs) |
| IL298681A (en) * | 2016-08-02 | 2023-01-01 | Univ Virginia Commonwealth | Preparations |
| JP7830313B2 (ja) * | 2019-09-30 | 2026-03-16 | デュレクト コーポレーション | アルコール性肝炎の処置 |
| CN115103591B (zh) * | 2019-12-27 | 2026-06-19 | 度勒科特公司 | 结晶性和液体结晶性25-羟基-胆甾-5-烯-3-硫酸钠及其制备方法 |
| CA3170320A1 (en) * | 2020-02-11 | 2021-08-19 | Durect Corporation | Treatment of infectious diseases |
| US12478603B2 (en) | 2020-03-31 | 2025-11-25 | The Regents Of The University Of Michigan | Serum metabolites as biomarkers for carnitine treatment of sepsis |
| JP2023527153A (ja) * | 2020-05-22 | 2023-06-27 | デュレクト コーポレーション | 非アルコール性脂肪性肝炎（ｎａｓｈ）の処置 |
| CA3187310A1 (en) | 2020-06-26 | 2021-12-30 | Durect Corporation | Use of oxygenated cholesterol sulfates for treating autoimmune conditions |
| CN112967234B (zh) * | 2021-02-09 | 2022-12-09 | 复旦大学附属中山医院 | 冠状动脉功能生理学病变模式定量评价方法 |
| US20240425545A1 (en) * | 2021-06-25 | 2024-12-26 | Durect Corporation | 25-Hydroxy-Cholest-5-En-3-Sulfate Choline and Methods for Preparing, and Uses of, Same |
| CN113750039B (zh) * | 2021-10-26 | 2023-08-18 | 浙江中医药大学 | 一种黄芩苷-海藻酸钙温敏纳米凝胶、制备方法及其应用 |
| WO2023196412A1 (en) * | 2022-04-06 | 2023-10-12 | Nobias Therapeutics, Inc. | Liquid formulations comprising mitogen-activated protein kinase kinase (mek) inhibitors and methods using same |
| CN119896674A (zh) * | 2023-10-27 | 2025-04-29 | 上海交通大学医学院附属新华医院 | 胆固醇硫酸酯在制备治疗特应性皮炎的药物中的应用 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| BE794362A (fr) | 1972-01-22 | 1973-07-23 | Merck Patent Gmbh | Sulfates hydrosolubles de sterine |
| US3928397A (en) | 1973-03-02 | 1975-12-23 | Eisai Co Ltd | New 5-cholestene derivatives and preparation thereof |
| US3822254A (en) | 1973-05-21 | 1974-07-02 | Hoffmann La Roche | Synthesis of 25-hydroxycholesterol |
| US4264512A (en) | 1975-09-29 | 1981-04-28 | The Regents Of The University Of California | 3-Deoxy-1α-hydroxy- and 3-deoxy-1α,25-dihydroxycholecalciferol and processes for the preparation thereof |
| US4202891A (en) | 1977-05-16 | 1980-05-13 | Kandutsch Andrew A | 15-Oxygenated sterol compounds and the use of such compounds to inhibit the biosynthesis of sterols |
| GB1595020A (en) | 1977-06-24 | 1981-08-05 | Chugai Pharmaceutical Co Ltd | 3a-hydroxy steroid derivatives of the cholestane series |
| US4427668A (en) | 1982-04-01 | 1984-01-24 | New York University | 26-Hydroxycholesterol and derivatives and analogs thereof in regulation of cholesterol accumulation in body tissue |
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4743597A (en) * | 1986-01-27 | 1988-05-10 | Javitt Norman B | Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases |
| US4863970A (en) | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
| US5510340A (en) | 1992-06-12 | 1996-04-23 | Sri International | Antihypercholesterolemic compounds and related pharmaceutical compositions and methods of use |
| US5371077A (en) | 1992-08-03 | 1994-12-06 | William Marsh Rice University | Side chain derivatized 15-oxygenated sterols, methods of using them and a process for preparing them |
| US5599659A (en) | 1993-03-11 | 1997-02-04 | Breonics, Inc. | Preservation solution for ex vivo, warm preservation of tissues, explants,organs and vascular endothelial cells comprising retinal-derived fibroblast growth factor, cyclodextrin and chondroitin sulfate |
| US5587368A (en) * | 1993-11-30 | 1996-12-24 | New York University | Administration of a 27-hydroxycholesterol or related compound or sterol-27-hydroxylase stimulant to prevent restenosis following vascular endothelial injury |
| ATE254628T1 (de) | 1995-06-23 | 2003-12-15 | Novo Nordisk As | Meiose regulierende verbindungen. |
| US6645953B2 (en) | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
| US20030153541A1 (en) | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
| JP2003522728A (ja) | 1998-05-13 | 2003-07-29 | ノボ ノルディスク アクティーゼルスカブ | 減数分裂調節化合物 |
| KR20010043558A (ko) | 1998-05-13 | 2001-05-25 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 감수분열 조절 화합물 |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US20060025393A1 (en) | 1999-04-30 | 2006-02-02 | Shutsung Liao | Steroid derivatives |
| JP2002543216A (ja) | 1999-04-30 | 2002-12-17 | アーチ ディベロップメント コーポレイション | ステロイド誘導体 |
| AU1291901A (en) | 1999-09-01 | 2001-03-26 | University Of British Columbia, The | Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| JP4018312B2 (ja) | 2000-02-21 | 2007-12-05 | 株式会社ルネサステクノロジ | 無線通信装置 |
| IN191090B (enExample) | 2000-08-29 | 2003-09-20 | Ranbanx Lab Ltd | |
| WO2002062302A2 (en) | 2001-02-08 | 2002-08-15 | The University Of Chicago | Steroidal derivatives |
| US20020164310A1 (en) | 2001-03-02 | 2002-11-07 | Mgvs Ltd. | Nucleic acid constructs, cells transformed therewith and methods utilizing same for inducing liver regeneration and alleviation of portal hypertension |
| JP4309661B2 (ja) | 2001-05-03 | 2009-08-05 | ザ ユニバーシティー オブ シカゴ | 肝臓ｘ受容体 |
| US20070197484A1 (en) | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| WO2003039480A2 (en) | 2001-11-08 | 2003-05-15 | The University Of Chicago | Method of treating disorder related to high cholesterol concentration |
| NZ537995A (en) * | 2002-08-20 | 2007-11-30 | Bristol Myers Squibb Co | Inclusion complex of aripiprazole in a substituted b-cyclodextrin |
| CA2568835C (en) | 2004-06-30 | 2014-05-27 | Janssen Pharmaceutica N.V. | Quinazolinone derivatives as parp inhibitors |
| WO2006047022A1 (en) * | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| US8399441B2 (en) | 2004-10-25 | 2013-03-19 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis |
| EP1983972A4 (en) | 2006-02-13 | 2012-01-25 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS |
| DE102006021181B3 (de) | 2006-05-06 | 2007-05-03 | Laux, Thomas, Dr. | Zahnprothesen-Trägerimplantat |
| GB0625965D0 (en) | 2006-12-23 | 2007-02-07 | Renovo Ltd | Medicaments for wound healing |
| US8003795B2 (en) | 2007-06-22 | 2011-08-23 | Cvi Pharmaceuticals Limited | Compounds and compositions for reducing lipid levels |
| US8831674B2 (en) | 2007-09-27 | 2014-09-09 | Multi-Tech Systems, Inc. | Message server |
| KR101098583B1 (ko) | 2008-01-04 | 2011-12-26 | 주식회사 엘지생명과학 | 세포, 조직 및 장기 보존 효과를 갖는 인돌 및 인다졸 유도체 |
| WO2011077245A2 (en) | 2009-12-23 | 2011-06-30 | Fondazione Centro San Raffaele Del Monte Tabor | Compositions |
| WO2012017290A1 (en) * | 2010-08-04 | 2012-02-09 | Carlo Ghisalberti | Inclusion complexes of cyclodextrins with spermidine, and proliferative/reparative compositions comprising thereof |
| KR101739816B1 (ko) * | 2010-12-01 | 2017-05-25 | 주식회사유한양행 | 레바프라잔 또는 그의 염을 함유하는 주사용 액제 조성물 또는 주사용 건조 분말 |
| US9034859B2 (en) * | 2011-04-06 | 2015-05-19 | Virginia Commonwealth University | Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
| HUE062616T2 (hu) | 2011-09-08 | 2023-11-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásaik |
| CN104220450B (zh) | 2012-04-12 | 2016-07-06 | 弗吉尼亚联邦大学 | 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5-胆甾烯-3β,25-二醇二硫酸酯(25HCDS) |
| CA2878946A1 (en) | 2012-07-17 | 2014-01-23 | Regents Of The University Of Michigan | Non-surgical method of treatment for cataract |
| CA2880880C (en) | 2012-08-03 | 2021-01-26 | John Mckew | Cyclodextrin for the treatment of lysosomal storage diseases |
| WO2014121235A2 (en) * | 2013-02-01 | 2014-08-07 | Zoneone Pharma, Inc. | Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes |
| EP2842547A1 (en) * | 2013-08-27 | 2015-03-04 | Freund Pharmatec Ltd. | Improved fenofibrate compositions |
| EA201990684A1 (ru) * | 2013-12-24 | 2020-12-30 | Вирджиния Коммонвелт Юниверсити | Способы применения оксигенированных холестеролсульфатов (ocs) |
| BR112017007053A2 (pt) * | 2014-10-07 | 2018-06-19 | Sage Therapeutics Inc | compostos neuroativos e métodos de utilização deste composto. |
| BR112017007025A2 (pt) | 2014-10-10 | 2017-12-12 | Univ Virginia Commonwealth | sulfatos de colesterol oxigenados para terapia de distúrbios causados por pelo menos um de atividade de leptina atenuada e um distúrbio de armazenamento de lipídio |
| WO2017019808A1 (en) | 2015-07-27 | 2017-02-02 | Catacore, Inc | Compositions for the treatment of cataracts |
| WO2018026837A1 (en) | 2016-08-02 | 2018-02-08 | Durect Corporation | Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride |
| WO2018026767A1 (en) | 2016-08-02 | 2018-02-08 | Virginia Commonwealth University | Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesions |
| IL298681A (en) * | 2016-08-02 | 2023-01-01 | Univ Virginia Commonwealth | Preparations |
| JP7830313B2 (ja) | 2019-09-30 | 2026-03-16 | デュレクト コーポレーション | アルコール性肝炎の処置 |
| CN115103591B (zh) | 2019-12-27 | 2026-06-19 | 度勒科特公司 | 结晶性和液体结晶性25-羟基-胆甾-5-烯-3-硫酸钠及其制备方法 |
| CA3170320A1 (en) | 2020-02-11 | 2021-08-19 | Durect Corporation | Treatment of infectious diseases |
| CN115803061A (zh) | 2020-05-22 | 2023-03-14 | 度勒科特公司 | 非酒精性脂肪性肝炎(nash)的治疗 |
| JP2023527153A (ja) | 2020-05-22 | 2023-06-27 | デュレクト コーポレーション | 非アルコール性脂肪性肝炎（ｎａｓｈ）の処置 |
| CA3187310A1 (en) | 2020-06-26 | 2021-12-30 | Durect Corporation | Use of oxygenated cholesterol sulfates for treating autoimmune conditions |
-
2017
- 2017-08-01 IL IL298681A patent/IL298681A/en unknown
- 2017-08-01 HR HRP20220932TT patent/HRP20220932T1/hr unknown
- 2017-08-01 CA CA3031224A patent/CA3031224A1/en active Pending
- 2017-08-01 CN CN202310244445.3A patent/CN116747233A/zh active Pending
- 2017-08-01 PT PT178375168T patent/PT3494125T/pt unknown
- 2017-08-01 ES ES17837516T patent/ES2922933T3/es active Active
- 2017-08-01 US US16/320,079 patent/US20190269695A1/en not_active Abandoned
- 2017-08-01 DK DK17837516.8T patent/DK3494125T3/da active
- 2017-08-01 RS RS20220815A patent/RS63529B1/sr unknown
- 2017-08-01 SI SI201731214T patent/SI3494125T1/sl unknown
- 2017-08-01 CN CN201780055805.8A patent/CN109983025B/zh active Active
- 2017-08-01 EA EA201990438A patent/EA201990438A1/ru unknown
- 2017-08-01 SM SM20220330T patent/SMT202200330T1/it unknown
- 2017-08-01 WO PCT/US2017/044840 patent/WO2018026781A1/en not_active Ceased
- 2017-08-01 KR KR1020197005371A patent/KR102465046B1/ko active Active
- 2017-08-01 PL PL17837516.8T patent/PL3494125T3/pl unknown
- 2017-08-01 TW TW112132920A patent/TWI920454B/zh active
- 2017-08-01 MX MX2019001323A patent/MX2019001323A/es unknown
- 2017-08-01 HU HUE17837516A patent/HUE059768T2/hu unknown
- 2017-08-01 JP JP2019505229A patent/JP2019524772A/ja active Pending
- 2017-08-01 LT LTEPPCT/US2017/044840T patent/LT3494125T/lt unknown
- 2017-08-01 AU AU2017305239A patent/AU2017305239C1/en active Active
- 2017-08-01 KR KR1020227038844A patent/KR102593667B1/ko active Active
- 2017-08-01 EP EP17837516.8A patent/EP3494125B1/en active Active
- 2017-08-01 EP EP22173674.7A patent/EP4101861A1/en active Pending
- 2017-08-01 KR KR1020237036153A patent/KR20230152787A/ko not_active Ceased
- 2017-08-01 TW TW106125936A patent/TWI815796B/zh active
-
2019
- 2019-01-22 IL IL264390A patent/IL264390B2/en unknown
- 2019-01-30 MX MX2022013429A patent/MX2022013429A/es unknown
-
2020
- 2020-11-10 US US17/094,432 patent/US11406646B2/en active Active
-
2022
- 2022-06-16 AU AU2022204217A patent/AU2022204217B2/en active Active
- 2022-06-28 US US17/852,142 patent/US12226423B2/en active Active
- 2022-08-01 JP JP2022122494A patent/JP7487264B2/ja active Active
- 2022-09-20 CY CY20221100625T patent/CY1125567T1/el unknown
-
2024
- 2024-05-08 JP JP2024075682A patent/JP2024105442A/ja active Pending
-
2025
- 2025-01-06 US US19/011,381 patent/US20250249021A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220932T1 (hr) | Sastavi koji sadrže 5-kolesten-3, 25-diol, 3-sulfat (25hc3s) ili njegovu farmaceutski prihvatljivu sol i barem jedan ciklički oligosaharid | |
| US9333190B2 (en) | Endoxifen compositions and methods | |
| US12318364B2 (en) | Isoflavonoid compositions and methods for the treatment of cancer | |
| JP2018537437A5 (enExample) | ||
| US20110137057A1 (en) | Unsaturated Steroid Compounds | |
| RU2013152751A (ru) | Лиофилизированный препарат цитотоксических дипептидов | |
| CN101242820A (zh) | 双（硫酰肼酰胺）调配物 | |
| JP6734971B2 (ja) | がん治療薬 | |
| ES2661106T3 (es) | Formulaciones de crema estabilizadas que comprenden aceite de sándalo | |
| US20130109700A1 (en) | Topical Itraconazole Formulations and Uses Thereof | |
| JP7597778B2 (ja) | シクロデキストリン及びブスルファンを含有する組成物 | |
| JP5788982B2 (ja) | ベンダムスチンアニオン性−カチオン性シクロポリサッカライド組成物 | |
| US20220249540A1 (en) | Inhalable composition compromising cyclodextrin for use in the treatment of nasal inflammations | |
| JP2019501191A5 (enExample) | ||
| Shang et al. | MSCs ameliorate hepatic IR injury by modulating phenotypic transformation of kupffer cells through drp-1 dependent mitochondrial dynamics | |
| CN107281165A (zh) | 一种雷公藤甲素‑叶酸靶向纳米药物及其制备方法和应用 | |
| HRP20201300T1 (hr) | Liofilizirani pripravak citotoksičnih dipeptida | |
| EP4288053A1 (en) | Small molecule inhibitors of cd38 as immunosuppressants | |
| EP3888637A1 (en) | Lyophilized preparation for prostaglandin e1 methyl ester injection, preparation thereof and application thereof | |
| CN102526038A (zh) | 替莫唑胺的脑靶向药物组合物及其应用 | |
| CN102552140B (zh) | 罗格列酮的液体组合物 | |
| CN102040643B (zh) | 环索奈德硝酸酯衍生物 | |
| CN102949725A (zh) | 一种含有糖皮质激素和nos抑制剂的注射药物组合物 | |
| CN104857014A (zh) | 2-羟丙基-β-环化糊精在制备治疗X-连锁肾上腺脑白质退化症的药物中的应用 | |
| AU2021374726A9 (en) | Compositions comprising methyl cyclodextrins for the treatment and/or prevention of hepatic steatosis |